Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 12/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677891 | 0.79 | SIGMAR1 (0.56) | TAAR1SLC6A2SIGMAR1MEN1KMT2A | |
| SCHEMBL2145927 | 0.78 | SLC6A2 (0.57) | TAAR1SLC6A2 | |
| SCHEMBL677907 | 0.78 | GFER (0.42) | TAAR1SLC6A2SIGMAR1ALDH1A1CYP3A4 | |
| SCHEMBL36323 | 0.77 | TAAR1 (0.67) | TAAR1SLC6A2ESR1ESR2CYP2C9 | |
| SCHEMBL20673669 | 0.77 | TAAR1 (0.67) | TAAR1SLC6A2ESR1ESR2MEN1 | |
| SCHEMBL3264679 | 0.77 | TAAR1 (0.67) | TAAR1SLC6A2ESR1ESR2SLC7A5 | |
| SCHEMBL20673668 | 0.77 | TAAR1 (0.67) | TAAR1SLC6A2ESR1ESR2MEN1 | |
| SCHEMBL678342 | 0.76 | KMT2A (0.53) | MEN1ALDH1A1KMT2A | |
| SCHEMBL677799 | 0.75 | SLC6A4 (0.60) | TAAR1SIGMAR1MEN1CYP1A2CYP2C19 | |
| SCHEMBL4692343 | 0.75 | TAAR1 (0.64) | TAAR1SLC6A2ESR1ESR2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275774-A1 | ORGANOANTIMONY COMPOUND, PROCESS FOR PREPARING SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH USE OF SAME, AND THE POLYMER | YAMAGO SHIGERU | 2011-11-10 | — | — | US | disclosed |
| US-8008414-B2 | Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-1767539-B1 | ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER | OTSUKA CHEMICAL CO LTD (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20090299008-A1 | Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer | OTSUKA CHEMICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-1767539-A1 | ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER | OTSUKA CHEMICAL COMPANY, LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299008-A1 | Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer | AOC2, ODC1, MCM7 | TAAR1 184/4885SLC6A2 4172/4885ESR1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.